Medical Device Global Market Access

This episode forecasts the state of medical technology mergers and acquisitions for 2026. We analyze whether the industry will see a return to large, transformative deals driven by the need to fill portfolio gaps in diagnostics, structural heart, and workflow assets, or if valuation discipline and integration risks will ensure the market remains focused on smaller, more selective acquisitions. - Will 2026 mark the return of mega-mergers in the medical device industry? - What portfolio gaps are large medtech companies trying to fill? - Why are diagnostics and structural heart technologies so attractive for acquisition? - How do high valuations and integration risks impact M&A decisions? - What role will regulatory scrutiny play in future deals? - Are smaller 'tuck-in' acquisitions a safer bet for growth? - How can companies prepare their regulatory strategy for post-merger integration? Successful M&A is just the first step; integrating a new portfolio and achieving global market access is the next challenge. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, ensuring your expanded product line meets international compliance. Our experts develop efficient regulatory strategies and use advanced AI to compile technical dossiers, streamlining submissions across 30+ markets. Whether you're a startup or a multinational enterprise navigating post-acquisition complexities, we provide the local expertise and data tools to accelerate your global growth. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools at https://pureglobal.ai.

This episode explores the significant impact that rising tariffs and supply-chain nationalism are projected to have on the medical technology industry by 2026. We dissect the four primary strategic responses available to MedTech firms: relocating production, diversifying sourcing networks, increasing prices, or absorbing shrinking profit margins. The host explains how these choices will be influenced by device category, reimbursement landscapes, and specific geopolitical tensions, urging companies to proactively plan for a new era of manufacturing and market access. Key Questions: - What is “supply-chain nationalism” and why is it a major threat to MedTech? - By 2026, how will new tariffs disrupt established manufacturing models? - Is relocating production (reshoring) a viable option for most device manufacturers? - How can companies redesign sourcing networks to mitigate geopolitical risks? - Will healthcare systems accept price increases driven by supply chain costs? - What happens to innovation if companies are forced to absorb lower profit margins? - Which device categories are most vulnerable to these global shifts? Navigating the challenges of tariffs and supply chain realignment demands a proactive, global regulatory strategy. Pure Global helps MedTech and IVD companies navigate this complexity. Our experts develop efficient pathways for regulatory approval and market access in over 30 countries, using advanced AI to compile technical dossiers and monitor regulatory changes. Whether you're assessing new markets to diversify your footprint or ensuring continuous compliance amidst shifting trade policies, we provide the local expertise and data-driven tools to secure your global presence. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools at https://pureglobal.ai.

This episode examines the immense pressures facing medical device manufacturers from Europe's Medical Device Regulation (MDR) and In-Vitro Diagnostic Regulation (IVDR) leading up to 2026. We explore the two potential outcomes: widespread "portfolio pruning" and market consolidation due to high compliance costs and Notified Body bottlenecks, or the successful reduction of these pressures by regulators before essential devices are removed from the market. Key Questions: - What are the biggest challenges manufacturers face with the EU MDR and IVDR transition? - Why is the year 2026 so critical for the European MedTech market? - What is "portfolio pruning" and how could it affect patient care? - Will the shortage of Notified Bodies lead to a market crisis? - How are companies deciding which products to keep and which to discontinue? - Could MDR and IVDR compliance costs force smaller companies out of the market? - What steps can be taken to reduce the regulatory bottlenecks in Europe? - Is industry consolidation an inevitable outcome of these new regulations? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies navigating complex landscapes like Europe's MDR/IVDR transition. We combine local expertise with advanced AI to streamline global market access, developing efficient regulatory strategies and compiling technical dossiers. Whether you are managing portfolio decisions or seeking new market entry, our team can help. Visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai to accelerate your global reach.

This episode delves into the upcoming 2026 Medical Device User Fee Amendments (MDUFA VI) negotiations and their profound impact on the U.S. medtech landscape. We explore how these negotiations will influence FDA review predictability, staffing stability, and fee structures, and what this means for the strategic planning of medical device companies, particularly startups and smaller innovators. - What are the Medical Device User Fee Amendments (MDUFA)? - Why are the 2026 negotiations critical for medtech innovation? - How does FDA review predictability affect a small company's fundraising and launch schedule? - What is the link between user fees and FDA staffing challenges? - Will the new MDUFA fee structure help or hinder smaller medtech firms? - How should companies adjust their regulatory strategy in anticipation of MDUFA VI? - What performance goals will the industry push for in the next MDUFA cycle? Navigating the U.S. FDA and other global markets requires expert strategy. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline market access. From developing efficient regulatory strategies and pre-submission activities for the FDA to acting as your local representative in over 30 markets, we ensure you can launch and maintain your products efficiently. Our technology-driven approach enhances accuracy and speed, helping you stay ahead. Visit our website at https://pureglobal.com/, contact us at [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the prediction that by 2026, the primary obstacle for AI medical devices will shift from technical validation to securing financial reimbursement. We discuss why clear payment pathways, understandable coding logic, and compelling health economic outcome evidence are becoming more critical than algorithmic accuracy for commercial success. This is a crucial look at the strategic planning required to navigate the evolving landscape of AI MedTech market access. Key Questions: - Why is technical accuracy no longer enough for AI medical device success? - What are the biggest reimbursement challenges facing AI MedTech in 2026? - How do payment pathways and coding logic determine commercial viability? - What kind of outcome evidence do health systems and payers actually require? - Is your AI device strategy prepared for the post-approval reimbursement bottleneck? - How can you build a reimbursement strategy from day one of product development? - What role does health economics play in market access for advanced AI tools? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We develop efficient pathways for regulatory approval and help you identify the best markets for expansion by leveraging your existing approvals. Our experts use advanced AI to compile and submit technical documents, ensuring you can navigate complex global requirements. Whether you're a startup or a multinational, we provide scalable solutions to get your innovation to market faster. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the future of the diabetes technology market, examining the critical tension between rapid innovation and foundational regulatory challenges. We analyze whether the competitive landscape leading into 2026 will be defined more by exciting advancements like fully closed-loop systems and longer-wear sensors, or by persistent issues such as product recalls, complaint handling, and software reliability. We discuss how market leaders must master both cutting-edge development and stringent post-market compliance to succeed. Key Questions: - How are fully closed-loop artificial pancreas systems set to redefine diabetes care? - What makes longer-wear CGM sensors a major competitive battleground? - Why have recalls and complaint handling become such significant hurdles for leading MedTech firms? - Is software reliability the most critical, yet overlooked, factor in automated insulin delivery? - How can manufacturers balance groundbreaking innovation with the demands of global regulators? - What will separate the market leaders from the followers in the diabetes tech space by 2026? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate these complex challenges. Our experts develop efficient pathways for regulatory approval, using advanced AI to compile and submit technical dossiers for devices, including complex Software as a Medical Device (SaMD). We also manage post-market surveillance and continuous regulatory monitoring to ensure you not only enter the market but maintain your presence securely. Let us help you balance innovation with compliance. Contact Pure Global at [email protected], visit us at https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the transformative potential of AI-enabled imaging and ultrasound tools designed for non-experts, set to reshape diagnostics by 2026. We dissect the four emerging business models—hardware, workflow software (SaMD), remote interpretation, and population-scale screening—and analyze the unique global regulatory, data privacy, and market access challenges associated with each. Discover which strategies are best positioned to succeed in this new era of decentralized healthcare. Key Questions: - How will AI empower non-specialists to use advanced ultrasound and imaging tools by 2026? - What are the four primary business models emerging from this technology shift? - What specific regulatory hurdles exist for AI-enabled hardware versus Software as a Medical Device (SaMD)? - How do data privacy laws like GDPR and HIPAA impact remote interpretation services? - What are the unique market access challenges for population-scale screening programs? - Why is a unified global regulatory strategy essential for success in this new market? - Which business model is best positioned to capture value by navigating these complexities? Navigating the complex regulatory landscape for AI-driven medical devices is critical. Pure Global specializes in helping innovative MedTech and IVD companies commercialize their products globally. We develop efficient regulatory strategies for complex technologies like Software as a Medical Device (SaMD) and AI-enabled hardware, helping you overcome market access hurdles in over 30 countries. Our integrated approach combines local expertise with advanced AI tools to streamline technical dossier submission and ensure ongoing compliance. To accelerate your global expansion, contact Pure Global at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.